68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Apr 9, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring two different types of imaging tests that help doctors see prostate cancer more clearly. The study is specifically looking at how well a new imaging agent called 68Ga-P16-093 works compared to a more established agent called 68Ga-PSMA-11 in patients who have been diagnosed with primary prostate cancer but have not yet received treatment. The goal is to find out which of these imaging tests is better at detecting not only the main tumor but also any spread of the cancer to other parts of the body.

To participate in this trial, men aged 65 to 75 years with confirmed untreated prostate cancer can sign up, provided they are willing to undergo both types of imaging tests within one week. Participants will need to give their written consent and should not have any known allergies to the imaging agents or other medical conditions that could affect their ability to participate. If you join the study, you can expect to undergo both imaging tests and contribute to important research that could improve how prostate cancer is diagnosed in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • histologically confirmed untreated primary prostate cancer patients;
• • 68Ga-PSMA-11 and 68Ga-P16-093 PET/CT within a week;
• • signed written consent.
• Exclusion Criteria:
• • known allergy against PSMA;
• • any medical condition that in the opinion of the investigator may significantly interfere with study compliance.